
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO(TM) in Canada from Knight
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO(TM) in Canada from Knight

Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO(TM) in Canada from Knight
Lir Life Sciences Corp. Formerly Blackbird Critical Metals Corp. Announces Closing of Acquisition of Lir Life Sciences Inc.
ASEP licenses anti-biofilm peptide tech to Bondent
Arch Biopartners Arranges Non-Brokered Private Placement
Theralase(R) Releases 3Q2025 Financial Statements
Briacell presents Bria-OTS+ preclinical results at SITC
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) at SITC 2025
Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update
ZYUS Life Sciences Corporation Announces Closing of First Tranche of Unit Offering and Issuance of Warrants Pursuant to Previously Announced Loan Agreements and Promissory Note Amendment
Quantum Biopharma Reports Strong Third Quarter Results Maintaining 'No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio
Light AI reports Financial Results for Three and Nine Months ended September 30, 2025
Pharmacorp Rx increases bought deal offering to $20M
Mindbio completes phase 2B dosing of depression trial
Ventripoint arranges $542,591 debt settlement
MedX Announces Final Closing of Non-Brokered Private Placement